Related Experiment Video

Updated: Sep 15, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.5K

Reduced-Dose versus Standard-Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study

Huiling Yan1, Dan Liu2, Juan Tong1

  • 1Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|July 17, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
annualised bleeding ratesannualised joint bleeding ratesemicizumabhaemophilia Areduced‐dosestandard‐dose

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K
Author Spotlight: Novel Intraperitoneal Injection Method for Zebrafish Cardiotoxicity Models
02:32

Author Spotlight: Novel Intraperitoneal Injection Method for Zebrafish Cardiotoxicity Models

Published on: March 29, 2024

2.0K

Related Experiment Videos

Last Updated: Sep 15, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.5K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K
Author Spotlight: Novel Intraperitoneal Injection Method for Zebrafish Cardiotoxicity Models
02:32

Author Spotlight: Novel Intraperitoneal Injection Method for Zebrafish Cardiotoxicity Models

Published on: March 29, 2024

2.0K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

178
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
178

Articles linked to this work by shared authors, journal, and citation graph.

Long-term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large-cohort retrospective study.

British journal of haematology·2026

Superior Efficacy and Deep Molecular Remission with Venetoclax Plus Hypomethylating Agent in Elderly Acute Myeloid Leukemia: A Real-World Comparative Cohort Study.

Clinical pharmacology : advances and applications·2026

Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.

Blood and lymphatic cancer : targets and therapy·2026

Development and Validation of a Novel Thrombosis Prediction Model for Adult Immune Thrombocytopenia (ITP-THROMBO).

Journal of blood medicine·2026

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.

Blood advances·2026

Revealing Decoherence Dependence of the Bright A Excitons on the Energy Positions of the Intervalley Dark Excitons in WS2 Semiconductors.

ACS nano·2025

Treatment Adherence in Haemophilia: Methods of Assessment, Clinical Outcomes, and Real-World Evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

DDAVP Challenges in 170 Children With von Willebrand Disease: Response Classification Varies According to Criteria Used.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Analysis of Annual Global Survey Reports for Haemophilia B in the Eastern Mediterranean Region: Disparities in Trends for A decade (2014-2023).

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Sensory and Clinical Characterization of Acute and Chronic Pain in Hemophilia: Identification of Distinct Pain Phenotypes.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Living With Factor VII Deficiency-A Mixed Methods Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Patient Preferences for the Treatment of Haemophilia A and B in France.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Role of Thrombectomy Technique in Alteplase Bridging Intravenous Thrombolysis for Basilar Artery Occlusion.

Journal of the American Heart Association·2026

Compound Heterozygous Mutations in FGA Cause Congenital Afibrinogenemia: A Case Report and Literature Review.

Birth defects research·2026

Anticoagulation Following Surgery for Glioblastoma: Case Report and Review of the Literature.

Journal of neurological surgery reports·2026

Jada System Versus Bakri Balloon for Postpartum Hemorrhage: A Retrospective Cohort Study.

Cureus·2026

Abnormally Low Hemoglobin A1c Due to a Heterozygous Alpha-Globin Variant (Hb I; HBA2 c.49A>G, p.Lys17Glu) in a Geriatric Patient.

Cureus·2026

Myeloablative Matched Sibling Donor Hematopoietic Stem Cell Transplantation as a Curative Treatment for Congenital Erythropoietic Porphyria: A Cohort Study from Low-Middle Income Country.

Missouri medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us